Amicus Therapeutics Financial Statements (FOLD)
|
|
|
|
Report date
|
|
|
24.02.2022 |
01.03.2023 |
28.02.2024 |
19.02.2025 |
20.02.2026 |
|
20.02.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
305.5 |
329.2 |
399.4 |
528.3 |
634.2 |
|
634.2 |
|
Operating Income, bln rub |
|
|
-206.4 |
-212.1 |
-77.2 |
24.9 |
34.5 |
|
32.8 |
|
EBITDA, bln rub |
? |
|
-202.9 |
-199.6 |
-92.1 |
29.4 |
53.8 |
|
53.8 |
|
Net profit, bln rub |
? |
|
-250.5 |
-236.6 |
-151.6 |
-56.1 |
-27.1 |
|
-27.1 |
|
|
OCF, bln rub |
? |
|
-202.5 |
-166.6 |
-69.1 |
-33.9 |
33.1 |
|
33.1 |
|
CAPEX, bln rub |
? |
|
3.88 |
3.77 |
7.44 |
3.55 |
3.30 |
|
3.30 |
|
FCF, bln rub |
? |
|
-206.4 |
-170.3 |
-76.5 |
-37.4 |
29.8 |
|
29.8 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
477.5 |
502.8 |
439.2 |
450.5 |
519.3 |
|
524.7 |
|
Cost of production, bln rub |
|
|
34.5 |
38.6 |
37.3 |
52.9 |
80.4 |
|
76.7 |
|
R&D, bln rub |
|
|
272.0 |
276.7 |
152.4 |
109.4 |
135.8 |
|
135.8 |
|
Interest expenses, bln rub |
|
|
32.5 |
37.1 |
50.1 |
49.6 |
46.2 |
|
46.2 |
|
|
Assets, bln rub |
|
|
905.1 |
724.2 |
777.9 |
785.0 |
949.9 |
|
949.9 |
|
Net Assets, bln rub |
? |
|
307.4 |
123.0 |
160.2 |
194.0 |
274.2 |
|
274.2 |
|
Debt, bln rub |
|
|
440.1 |
452.1 |
445.1 |
443.6 |
483.3 |
|
483.3 |
|
Cash, bln rub |
|
|
482.5 |
293.6 |
286.2 |
249.9 |
293.5 |
|
293.5 |
|
Net debt, bln rub |
|
|
-42.4 |
158.5 |
158.9 |
193.7 |
189.8 |
|
189.8 |
|
|
Ordinary share price, rub |
|
|
11.6 |
12.2 |
14.2 |
9.42 |
14.2 |
|
10.9 |
|
Number of ordinary shares, mln |
|
|
271.4 |
289.1 |
295.2 |
304.4 |
308.4 |
|
309.0 |
|
|
Market cap, bln rub |
|
|
3 135 |
3 529 |
4 188 |
2 867 |
4 391 |
|
3 381 |
|
EV, bln rub |
? |
|
3 093 |
3 688 |
4 347 |
3 061 |
4 581 |
|
3 571 |
|
Book value, bln rub |
|
|
87 |
-98 |
-58 |
-21 |
63 |
|
63 |
|
|
EPS, rub |
? |
|
-0.92 |
-0.82 |
-0.51 |
-0.18 |
-0.09 |
|
-0.09 |
|
FCF/share, rub |
|
|
-0.76 |
-0.59 |
-0.26 |
-0.12 |
0.10 |
|
0.10 |
|
BV/share, rub |
|
|
0.32 |
-0.34 |
-0.20 |
-0.07 |
0.20 |
|
0.20 |
|
|
EBITDA margin, % |
? |
|
-66.4% |
-60.6% |
-23.1% |
5.56% |
8.48% |
|
8.48% |
|
Net margin, % |
? |
|
-82.0% |
-71.9% |
-38.0% |
-10.6% |
-4.27% |
|
-4.27% |
|
FCF yield, % |
? |
|
-6.58% |
-4.83% |
-1.83% |
-1.31% |
0.68% |
|
0.88% |
|
ROE, % |
? |
|
-81.5% |
-192.3% |
-94.6% |
-28.9% |
-9.89% |
|
-9.89% |
|
ROA, % |
? |
|
-27.7% |
-32.7% |
-19.5% |
-7.15% |
-2.85% |
|
-2.85% |
|
|
P/E |
? |
|
-12.5 |
-14.9 |
-27.6 |
-51.1 |
-162.0 |
|
-124.7 |
|
P/FCF |
|
|
-15.2 |
-20.7 |
-54.7 |
-76.6 |
147.1 |
|
113.3 |
|
P/S |
? |
|
10.3 |
10.7 |
10.5 |
5.43 |
6.92 |
|
5.33 |
|
P/BV |
? |
|
36.2 |
-36.1 |
-72.1 |
-136.9 |
70.2 |
|
54.1 |
|
EV/EBITDA |
? |
|
-15.2 |
-18.5 |
-47.2 |
104.2 |
85.1 |
|
66.4 |
|
Debt/EBITDA |
|
|
0.21 |
-0.79 |
-1.73 |
6.59 |
3.53 |
|
3.53 |
|
|
R&D/CAPEX, % |
|
|
7 004% |
7 347% |
2 048% |
3 078% |
4 121% |
|
4 121% |
|
|
CAPEX/Revenue, % |
|
|
1.27% |
1.14% |
1.86% |
0.67% |
0.52% |
|
0.52% |
|
| Amicus Therapeutics shareholders |
